APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Chorionic Gonadotropin (HCG)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Chorionic Gonadotropin (HCG) Market Outlook and Growth Opportunities 2026

22 December 2025204 pages

Choose your research edition.

Industry ResearchHuman Chorionic Gonadotropin (HCG) Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Chorionic Gonadotropin (HCG) Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Human Chorionic Gonadotropin (HCG) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Chorionic Gonadotropin (HCG) Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Chorionic Gonadotropin (HCG) Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Human Chorionic Gonadotropin (HCG) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Chorionic Gonadotropin (HCG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Chorionic Gonadotropin (HCG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Chorionic Gonadotropin (HCG) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Chorionic Gonadotropin (HCG) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Chorionic Gonadotropin (HCG) market include Sun Pharmaceutical Industries Ltd, Ferring B.V, Fresenius Kabi AG, Zydus Lifesciences Ltd, VHB Medi Sciences Limited, Serum Institute of India Pvt. Ltd, Scripps Laboratories, Sanzyme and Merck & Co., Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Chorionic Gonadotropin (HCG) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Chorionic Gonadotropin (HCG) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Chorionic Gonadotropin (HCG) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Chorionic Gonadotropin (HCG) market.

Human Chorionic Gonadotropin (HCG) Segment by Company

Sun Pharmaceutical Industries Ltd

Ferring B.V

Fresenius Kabi AG

Zydus Lifesciences Ltd

VHB Medi Sciences Limited

Serum Institute of India Pvt. Ltd

Scripps Laboratories

Sanzyme

Merck & Co., Inc

LUPIN

Leebio

Kamiya Biomedical Company

EMD Serono, Inc

Corona Remedies Pvt. Ltd.

Cigna

Bristol Myers Squibb Company

Human Chorionic Gonadotropin (HCG) Segment by Type

Natural Source Extraction

Recombinant DNA Technology

Human Chorionic Gonadotropin (HCG) Segment by Application

Cryptorchidism Treatment

Oligospermic Treatment

Female Infertility Treatment

Others

Human Chorionic Gonadotropin (HCG) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Chorionic Gonadotropin (HCG) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Chorionic Gonadotropin (HCG) key companies, revenue, market share, and recent developments.

3. To split the Human Chorionic Gonadotropin (HCG) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Chorionic Gonadotropin (HCG) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Chorionic Gonadotropin (HCG) significant trends, drivers, influence factors in global and regions.

6. To analyze Human Chorionic Gonadotropin (HCG) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Chorionic Gonadotropin (HCG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Chorionic Gonadotropin (HCG) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Chorionic Gonadotropin (HCG).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Chorionic Gonadotropin (HCG) industry.

Chapter 3: Detailed analysis of Human Chorionic Gonadotropin (HCG) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Chorionic Gonadotropin (HCG) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Chorionic Gonadotropin (HCG) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Chorionic Gonadotropin (HCG) Industry Trends Table 2. Human Chorionic Gonadotropin (HCG) Industry Drivers Table 3. Human Chorionic Gonadotropin (HCG) Industry Opportunities and Challenges Table 4. Human Chorionic Gonadotropin (HCG) Industry Restraints Table 5. Global Human Chorionic Gonadotropin (HCG) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Chorionic Gonadotropin (HCG) Revenue Share by Company (2021-2026) Table 7. Global Human Chorionic Gonadotropin (HCG) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Chorionic Gonadotropin (HCG) Key Company Manufacturing Base & Headquarters Table 9. Global Human Chorionic Gonadotropin (HCG) Company, Product Type & Application Table 10. Global Human Chorionic Gonadotropin (HCG) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Chorionic Gonadotropin (HCG) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Natural Source Extraction Table 15. Significant Companies of Recombinant DNA Technology Table 16. Global Human Chorionic Gonadotropin (HCG) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Human Chorionic Gonadotropin (HCG) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Human Chorionic Gonadotropin (HCG) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Type (2021-2026) Table 20. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cryptorchidism Treatment Table 22. Significant Companies of Oligospermic Treatment Table 23. Significant Companies of Female Infertility Treatment Table 24. Significant Companies of Others Table 25. Global Human Chorionic Gonadotropin (HCG) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Chorionic Gonadotropin (HCG) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Human Chorionic Gonadotropin (HCG) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Application (2021-2026) Table 29. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Application (2027-2032) Table 30. Global Human Chorionic Gonadotropin (HCG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Human Chorionic Gonadotropin (HCG) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Region (2021-2026) Table 33. Global Human Chorionic Gonadotropin (HCG) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Region (2027-2032) Table 35. Global Human Chorionic Gonadotropin (HCG) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Human Chorionic Gonadotropin (HCG) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Human Chorionic Gonadotropin (HCG) Sales Value Market Share by Country (2021-2026) Table 38. Global Human Chorionic Gonadotropin (HCG) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Human Chorionic Gonadotropin (HCG) Sales Value Market Share by Country (2027-2032) Table 40. Sun Pharmaceutical Industries Ltd Company Information Table 41. Sun Pharmaceutical Industries Ltd Business Overview Table 42. Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio Table 44. Sun Pharmaceutical Industries Ltd Recent Development Table 45. Ferring B.V Company Information Table 46. Ferring B.V Business Overview Table 47. Ferring B.V Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Ferring B.V Human Chorionic Gonadotropin (HCG) Product Portfolio Table 49. Ferring B.V Recent Development Table 50. Fresenius Kabi AG Company Information Table 51. Fresenius Kabi AG Business Overview Table 52. Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Product Portfolio Table 54. Fresenius Kabi AG Recent Development Table 55. Zydus Lifesciences Ltd Company Information Table 56. Zydus Lifesciences Ltd Business Overview Table 57. Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio Table 59. Zydus Lifesciences Ltd Recent Development Table 60. VHB Medi Sciences Limited Company Information Table 61. VHB Medi Sciences Limited Business Overview Table 62. VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Product Portfolio Table 64. VHB Medi Sciences Limited Recent Development Table 65. Serum Institute of India Pvt. Ltd Company Information Table 66. Serum Institute of India Pvt. Ltd Business Overview Table 67. Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio Table 69. Serum Institute of India Pvt. Ltd Recent Development Table 70. Scripps Laboratories Company Information Table 71. Scripps Laboratories Business Overview Table 72. Scripps Laboratories Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Scripps Laboratories Human Chorionic Gonadotropin (HCG) Product Portfolio Table 74. Scripps Laboratories Recent Development Table 75. Sanzyme Company Information Table 76. Sanzyme Business Overview Table 77. Sanzyme Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanzyme Human Chorionic Gonadotropin (HCG) Product Portfolio Table 79. Sanzyme Recent Development Table 80. Merck & Co., Inc Company Information Table 81. Merck & Co., Inc Business Overview Table 82. Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Product Portfolio Table 84. Merck & Co., Inc Recent Development Table 85. LUPIN Company Information Table 86. LUPIN Business Overview Table 87. LUPIN Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. LUPIN Human Chorionic Gonadotropin (HCG) Product Portfolio Table 89. LUPIN Recent Development Table 90. Leebio Company Information Table 91. Leebio Business Overview Table 92. Leebio Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Leebio Human Chorionic Gonadotropin (HCG) Product Portfolio Table 94. Leebio Recent Development Table 95. Kamiya Biomedical Company Company Information Table 96. Kamiya Biomedical Company Business Overview Table 97. Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Product Portfolio Table 99. Kamiya Biomedical Company Recent Development Table 100. EMD Serono, Inc Company Information Table 101. EMD Serono, Inc Business Overview Table 102. EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Product Portfolio Table 104. EMD Serono, Inc Recent Development Table 105. Corona Remedies Pvt. Ltd. Company Information Table 106. Corona Remedies Pvt. Ltd. Business Overview Table 107. Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Product Portfolio Table 109. Corona Remedies Pvt. Ltd. Recent Development Table 110. Cigna Company Information Table 111. Cigna Business Overview Table 112. Cigna Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Cigna Human Chorionic Gonadotropin (HCG) Product Portfolio Table 114. Cigna Recent Development Table 115. Bristol Myers Squibb Company Company Information Table 116. Bristol Myers Squibb Company Business Overview Table 117. Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Product Portfolio Table 119. Bristol Myers Squibb Company Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Human Chorionic Gonadotropin (HCG) Product Image Figure 2. Global Human Chorionic Gonadotropin (HCG) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Chorionic Gonadotropin (HCG) Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Chorionic Gonadotropin (HCG) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Natural Source Extraction Image Figure 8. Recombinant DNA Technology Image Figure 9. Global Human Chorionic Gonadotropin (HCG) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Human Chorionic Gonadotropin (HCG) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Type (2021-2032) Figure 12. Cryptorchidism Treatment Image Figure 13. Oligospermic Treatment Image Figure 14. Female Infertility Treatment Image Figure 15. Others Image Figure 16. Global Human Chorionic Gonadotropin (HCG) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Human Chorionic Gonadotropin (HCG) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Application (2021-2032) Figure 19. Global Human Chorionic Gonadotropin (HCG) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Human Chorionic Gonadotropin (HCG) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Human Chorionic Gonadotropin (HCG) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Human Chorionic Gonadotropin (HCG) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Human Chorionic Gonadotropin (HCG) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Human Chorionic Gonadotropin (HCG) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Natural Source Extraction
  • Recombinant DNA Technology
Applications
  • Cryptorchidism Treatment
  • Oligospermic Treatment
  • Female Infertility Treatment
  • Others
Companies covered
  • Sun Pharmaceutical Industries Ltd
  • Ferring B.V
  • Fresenius Kabi AG
  • Zydus Lifesciences Ltd
  • VHB Medi Sciences Limited
  • Serum Institute of India Pvt. Ltd
  • Scripps Laboratories
  • Sanzyme
  • Merck & Co., Inc
  • LUPIN
  • Leebio
  • Kamiya Biomedical Company
  • EMD Serono, Inc
  • Corona Remedies Pvt. Ltd.
  • Cigna
  • Bristol Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Chorionic Gonadotropin (HCG) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Chorionic Gonadotropin (HCG) Market Dynamics
  1. 2.1 Human Chorionic Gonadotropin (HCG) Industry Trends
  2. 2.2 Human Chorionic Gonadotropin (HCG) Industry Drivers
  3. 2.3 Human Chorionic Gonadotropin (HCG) Industry Opportunities and Challenges
  4. 2.4 Human Chorionic Gonadotropin (HCG) Industry Restraints
3 Human Chorionic Gonadotropin (HCG) Market by Company
  1. 3.1 Global Human Chorionic Gonadotropin (HCG) Company Revenue Ranking in 2025
  2. 3.2 Global Human Chorionic Gonadotropin (HCG) Revenue by Company (2021-2026)
  3. 3.3 Global Human Chorionic Gonadotropin (HCG) Company Ranking (2024-2026)
  4. 3.4 Global Human Chorionic Gonadotropin (HCG) Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Chorionic Gonadotropin (HCG) Company Product Type and Application
  6. 3.6 Global Human Chorionic Gonadotropin (HCG) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Chorionic Gonadotropin (HCG) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Chorionic Gonadotropin (HCG) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Chorionic Gonadotropin (HCG) Market by Type
  1. 4.1 Human Chorionic Gonadotropin (HCG) Type Introduction
  2. 4.1.1 Natural Source Extraction
  3. 4.1.2 Recombinant DNA Technology
  4. 4.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Type
  5. 4.2.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Type (2021-2032)
  7. 4.2.3 Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Type (2021-2032)
5 Human Chorionic Gonadotropin (HCG) Market by Application
  1. 5.1 Human Chorionic Gonadotropin (HCG) Application Introduction
  2. 5.1.1 Cryptorchidism Treatment
  3. 5.1.2 Oligospermic Treatment
  4. 5.1.3 Female Infertility Treatment
  5. 5.1.4 Others
  6. 5.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Application
  7. 5.2.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Application (2021-2032)
  9. 5.2.3 Global Human Chorionic Gonadotropin (HCG) Sales Value Share by Application (2021-2032)
6 Human Chorionic Gonadotropin (HCG) Regional Value Analysis
  1. 6.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032)
  7. 6.3.2 North America Human Chorionic Gonadotropin (HCG) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032)
  10. 6.4.2 Europe Human Chorionic Gonadotropin (HCG) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Chorionic Gonadotropin (HCG) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032)
  16. 6.6.2 South America Human Chorionic Gonadotropin (HCG) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Chorionic Gonadotropin (HCG) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Chorionic Gonadotropin (HCG) Sales Value Share by Country, 2025 VS 2032
7 Human Chorionic Gonadotropin (HCG) Country-level Value Analysis
  1. 7.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Chorionic Gonadotropin (HCG) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Chorionic Gonadotropin (HCG) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Chorionic Gonadotropin (HCG) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Chorionic Gonadotropin (HCG) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Chorionic Gonadotropin (HCG) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceutical Industries Ltd
  2. 8.1.1 Sun Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Sun Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
  6. 8.1.5 Sun Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Ferring B.V
  8. 8.2.1 Ferring B.V Company Information
  9. 8.2.2 Ferring B.V Business Overview
  10. 8.2.3 Ferring B.V Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferring B.V Human Chorionic Gonadotropin (HCG) Product Portfolio
  12. 8.2.5 Ferring B.V Recent Developments
  13. 8.3 Fresenius Kabi AG
  14. 8.3.1 Fresenius Kabi AG Company Information
  15. 8.3.2 Fresenius Kabi AG Business Overview
  16. 8.3.3 Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Product Portfolio
  18. 8.3.5 Fresenius Kabi AG Recent Developments
  19. 8.4 Zydus Lifesciences Ltd
  20. 8.4.1 Zydus Lifesciences Ltd Company Information
  21. 8.4.2 Zydus Lifesciences Ltd Business Overview
  22. 8.4.3 Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
  24. 8.4.5 Zydus Lifesciences Ltd Recent Developments
  25. 8.5 VHB Medi Sciences Limited
  26. 8.5.1 VHB Medi Sciences Limited Company Information
  27. 8.5.2 VHB Medi Sciences Limited Business Overview
  28. 8.5.3 VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Product Portfolio
  30. 8.5.5 VHB Medi Sciences Limited Recent Developments
  31. 8.6 Serum Institute of India Pvt. Ltd
  32. 8.6.1 Serum Institute of India Pvt. Ltd Company Information
  33. 8.6.2 Serum Institute of India Pvt. Ltd Business Overview
  34. 8.6.3 Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
  36. 8.6.5 Serum Institute of India Pvt. Ltd Recent Developments
  37. 8.7 Scripps Laboratories
  38. 8.7.1 Scripps Laboratories Company Information
  39. 8.7.2 Scripps Laboratories Business Overview
  40. 8.7.3 Scripps Laboratories Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Scripps Laboratories Human Chorionic Gonadotropin (HCG) Product Portfolio
  42. 8.7.5 Scripps Laboratories Recent Developments
  43. 8.8 Sanzyme
  44. 8.8.1 Sanzyme Company Information
  45. 8.8.2 Sanzyme Business Overview
  46. 8.8.3 Sanzyme Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanzyme Human Chorionic Gonadotropin (HCG) Product Portfolio
  48. 8.8.5 Sanzyme Recent Developments
  49. 8.9 Merck & Co., Inc
  50. 8.9.1 Merck & Co., Inc Company Information
  51. 8.9.2 Merck & Co., Inc Business Overview
  52. 8.9.3 Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Product Portfolio
  54. 8.9.5 Merck & Co., Inc Recent Developments
  55. 8.10 LUPIN
  56. 8.10.1 LUPIN Company Information
  57. 8.10.2 LUPIN Business Overview
  58. 8.10.3 LUPIN Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LUPIN Human Chorionic Gonadotropin (HCG) Product Portfolio
  60. 8.10.5 LUPIN Recent Developments
  61. 8.11 Leebio
  62. 8.11.1 Leebio Company Information
  63. 8.11.2 Leebio Business Overview
  64. 8.11.3 Leebio Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Leebio Human Chorionic Gonadotropin (HCG) Product Portfolio
  66. 8.11.5 Leebio Recent Developments
  67. 8.12 Kamiya Biomedical Company
  68. 8.12.1 Kamiya Biomedical Company Company Information
  69. 8.12.2 Kamiya Biomedical Company Business Overview
  70. 8.12.3 Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Product Portfolio
  72. 8.12.5 Kamiya Biomedical Company Recent Developments
  73. 8.13 EMD Serono, Inc
  74. 8.13.1 EMD Serono, Inc Company Information
  75. 8.13.2 EMD Serono, Inc Business Overview
  76. 8.13.3 EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Product Portfolio
  78. 8.13.5 EMD Serono, Inc Recent Developments
  79. 8.14 Corona Remedies Pvt. Ltd.
  80. 8.14.1 Corona Remedies Pvt. Ltd. Company Information
  81. 8.14.2 Corona Remedies Pvt. Ltd. Business Overview
  82. 8.14.3 Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Product Portfolio
  84. 8.14.5 Corona Remedies Pvt. Ltd. Recent Developments
  85. 8.15 Cigna
  86. 8.15.1 Cigna Company Information
  87. 8.15.2 Cigna Business Overview
  88. 8.15.3 Cigna Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cigna Human Chorionic Gonadotropin (HCG) Product Portfolio
  90. 8.15.5 Cigna Recent Developments
  91. 8.16 Bristol Myers Squibb Company
  92. 8.16.1 Bristol Myers Squibb Company Company Information
  93. 8.16.2 Bristol Myers Squibb Company Business Overview
  94. 8.16.3 Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Product Portfolio
  96. 8.16.5 Bristol Myers Squibb Company Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst